Lu et al. [1] have assessed the value of an AAb assay to a panel of TAAs comprised of MUC1, HER2, p53 and IGFBP2 as a diagnostic tool for breast carcinoma. This evidence concerns the gene IGFBP2 and breast carcinoma.